Home Press Release Immune Repertoire Sequencing Market Size Projected to Reach $872.66 million by 2034 | 10.28%

Immune Repertoire Sequencing Market Size Projected to Reach $872.66 million by 2034 | 10.28%

23 Jul, 2026

According to Straits Research, the global immune repertoire sequencing market size was valued at $362.96 million in 2025 and is projected to reach $872.66 million by 2034, registering a CAGR of 10.28% during the forecast period 2026–2034.

Market Dynamics

The immune repertoire sequencing market is driven by rising adoption of detailed T cell and B cell profiling in oncology, infectious disease monitoring, and cell therapy development, as research groups and biopharma companies increasingly rely on receptor level insights to guide therapy evaluation and biomarker discovery. The market faces restraint due to limited availability of diverse reference datasets and the technical complexity associated with interpreting large scale immune sequencing outputs, which creates barriers for laboratories with constrained computational capacity or limited access to trained personnel. Despite these challenges, the market presents a growing opportunity through the expansion of regional immunology data networks and multi institutional collaborations that aim to standardize immune profiling workflows, broaden population level datasets, and encourage uptake of advanced sequencing platforms and bioinformatics solutions across research and clinical ecosystems.

Market Segments

  1. By Product Type (2026-2034)
    1. Reagents & Kits
      1. DNA Extraction Kits
      2. RNA Extraction Kits
      3. Library Preparation Kits
      4. Target Enrichment Kits
      5. PCR Amplification Kits
      6. Others
    2. Sequencing Platforms
      1. Illumina Platforms 
      2. Oxford Nanopore
      3. PacBio Systems
      4. Others
    3. Software & Services
      1. Data Analysis Software
      2. Bioinformatics Services
      3. Cloud-Based Platforms
      4. Custom Sequencing Services
      5. Others
  2. By Application (2026-2034)
    1. Oncology & Cancer Immunotherapy
    2. Autoimmune & Inflammatory Diseases
    3. Infectious Diseases & Vaccine Development
    4. Transplantation & Immune Tolerance
    5. Others
  3. By End User (2026-2034)
    1. Pharmaceutical & Biotechnology Companies
    2. Academic & Research Institutes
    3. Hospitals & Clinical Labs
    4. Contract Research Organizations (CROs)
    5. Government & Regulatory Bodies
    6. Others